Compare SIDU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | AGEN |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.4M | 274.8M |
| IPO Year | 2021 | 1999 |
| Metric | SIDU | AGEN |
|---|---|---|
| Price | $1.93 | $7.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 3.1M | 977.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.94 | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | $3,383,878.00 | ★ $42,877,086.00 |
| Revenue This Year | $171.29 | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.23 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $0.63 | $2.71 |
| 52 Week High | $6.79 | $8.85 |
| Indicator | SIDU | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 47.99 |
| Support Level | $1.73 | $2.97 |
| Resistance Level | $3.12 | $8.64 |
| Average True Range (ATR) | 0.11 | 0.49 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 4.65 | 25.27 |
Sidus Space Inc is a space and defense technology company with core capabilities that include dual use satellite manufacturing & technology integration, AI products and services, space and defense hardware components and space-based data solutions. The company generates revenue through a combination of: Satellite platform sales and customization, Payload hosting and mission services, Engineering and systems integration services, and Space and defense hardware manufacturing. The firm supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers. The firm generates revenue principally from satellite platform and payload hosting contracts, manufacturing and engineering services, mission operations, and sales of proprietary hardware products.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.